Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6681)

COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Sole Overall Coordinator, Placing Agent and Capital Market Intermediary

國泰海通 GUOTAI HAITONG | 國泰君安國際 GUOTAI JUNAN INTERNATIONAL

The Board is pleased to announce that the completion of the Placing took place on 27 January 2026 in accordance with the terms and conditions of the Placing and Subscription Agreement, where an aggregate of 92,000,000 Placing Shares were successfully placed by the Placing Agent, on a best effort basis, to not less than six (6) Placees, at the Placing Price of HK$5.6 for each Placing Share. To the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, the Placees and their ultimate beneficial owners are Independent Third Parties.

As all conditions for the completion of the Top-up Subscription had been fulfilled, the Company allotted and issued 92,000,000 Top-up Subscription Shares to the Seller at HK$5.6 per Top-up Subscription Share on 5 February 2026 in accordance with the terms and conditions of the Placing and Subscription Agreement.

Reference is made to the announcements of the Company dated 23 January 2026 and 27 January 2026 (the "**Announcements**") in respect of, among others, the Placing and the Top-up Subscription. Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE PLACING AND THE TOP-UP SUBSCRIPTION

The Board is pleased to announce that the completion of the Placing took place on 27 January 2026 in accordance with the terms and conditions of the Placing and Subscription Agreement, where an aggregate of 92,000,000 Placing Shares were successfully placed by the Placing Agent, on a best effort basis, to not less than six (6) Placees, at the Placing Price of HK$5.6 for each Placing Share. To the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, the Placees and their ultimate beneficial owners are Independent Third Parties. None of the Placees became a substantial shareholder of the Company immediately after the completion of the Placing. As all conditions for the completion of the Top-up Subscription had been fulfilled, the Company allotted and issued 92,000,000 Top-up Subscription Shares to the Seller at HK$5.6 per Top-up Subscription Share on 5 February 2026 in accordance with the terms and conditions of the Placing and Subscription Agreement.

The aggregate net proceeds from the Top-up Subscription, after deducting all relevant fees, costs and expenses (including but not limited to legal expenses and disbursements) incidental to the Placing and the Top-up Subscription, amounted to approximately HK$500.68 million.

EFFECT ON THE SHAREHOLDING OF THE COMPANY FOLLOWING COMPLETION OF THE PLACING AND THE TOP-UP SUBSCRIPTION

The table below sets out the shareholding structure of the Company (i) immediately before the completion of the Placing and the Top-up Subscription; (ii) immediately following the completion of the Placing but before the completion of the Top-up Subscription; and (iii) immediately following the completion of the Placing and the Top-up Subscription:

	Immediately before the completion of the Placing and the Top-up Subscription		**Immediately following the completion of the Placing but before the completion of the Top-up Subscription**		**Immediately following the completion of the Placing and the Top-up Subscription**	
	Number of Shares	*Approximate %*	*Number of Shares*	*Approximate %*	*Number of Shares*	*Approximate %*
Shareholders:						
Concerted Parties [(1)]:						
ZTan Limited [(2)]	275,468,000	21.75%	183,468,000	14.49%	275,468,000	20.28%
Healthblooming Limited [(3)]	59,104,000	4.67%	59,104,000	4.67%	59,104,000	4.35%
Wispirits Limited [(4)]	109,052,000	8.61%	109,052,000	8.61%	109,052,000	8.03%
Wiseforward Limited [(5)]	44,503,000	3.51%	44,503,000	3.51%	44,503,000	3.28%
Neurobright Limited [(6)]	30,400,000	2.40%	30,400,000	2.40%	30,400,000	2.24%
Sub-total	**518,527,000**	**40.95%**	**426,527,000**	**33.68%**	**518,527,000**	**38.18%**
Other non-public Shareholders:						
Core connected persons [(7)]	335,547,000	26.50%	335,547,000	26.50%	335,547,000	24.70%

	Immediately before the completion of the Placing and the Top-up Subscription		Immediately following the completion of the Placing but before the completion of the Top-up Subscription		Immediately following the completion of the Placing and the Top-up Subscription	
	Number of Shares	*Approximate %*	*Number of Shares*	*Approximate %*	*Number of Shares*	*Approximate %*
Public Shareholders:						
The Placees	0	0.00%	92,000,000	7.27%	92,000,000	6.77%
Other public Shareholders	412,204,000	32.55%	412,204,000	32.55%	412,204,000	30.35%
Sub-total	**412,204,000**	**32.55%**	**504,204,000**	**39.82%**	**504,204,000**	**37.12%**
Total	**1,266,278,000**	**100.00%**	**1,266,278,000**	**100.00%**	**1,358,278,000**	**100.00%**

Notes:

(1) Pursuant to the Offshore AIC Agreement (as defined in the Prospectus), Mr. Tan Zheng, Dr. Wang Xiaoyi, ZTan Limited and Wispirits Limited agreed to act in concert for so long as they remain interested in the shares of the Company, consult each other and reach a consensus before voting at the board meetings and shareholders' meetings of the Company, and in case the parties fail to reach a consensus, vote based on the opinion of Mr. Tan Zheng. Accordingly, Mr. Tan Zheng and Dr. Wang Xiaoyi, together with their respective close associates, namely ZTan Limited, Wispirits Limited, Wiseforward Limited and Neurobright Limited are the controlling shareholders of the Company.

(2) The Seller, a British Virgin Islands company wholly owned by Mr. Tan Zheng, our executive Director, chairman of the Board and chief strategy officer of the Company.

(3) Pursuant to the Voting Proxy Agreement (as defined in the Prospectus), Healthblooming Limited have granted voting rights in the Company to Mr. Tan Zheng.

(4) A British Virgin Islands company wholly owned by Dr. Wang Xiaoyi.

(5) A British Virgin Islands company which voting rights are controlled by Dr. Wang Xiaoyi.

(6) A British Virgin Islands company which voting rights are controlled by Dr. Wang Xiaoyi.

(7) This represents the sum of (i) 123,527,000 Shares that Ms. Li Mingqiu, our non-executive Director, deemed to be interested; (ii) 126,854,000 Shares that Mr. Deng Feng, our non-executive Director, deemed to be interested; and (iii) 85,166,000 Shares held by Wisdomspirit Holding Limited, a wholly owned entity of Trident Trust Company (HK) Limited, the trustee of the trust established pursuant to the Pre-IPO Share Award Scheme of which Mr. Tan Zheng and Dr. Wang Xiaoyi is each a beneficiary.

USE OF PROCEEDS

As disclosed in the Announcements, upon completion of the Placing and the Top-up Subscription, the total net proceeds, after deducting all relevant fees, costs and expenses (including but not limited to legal expenses and disbursements), are estimated to be approximately HK$500.68 million.

The Company intends to use the net proceeds of the Top-up Subscription (a) to fund research and development initiatives; (b) for domestic and international market development; (c) for strategic investments and acquisitions; and (d) to supplement the working capital of the Company and its subsidiaries for general corporate purposes. For further details, please refer to the section headed "REASONS FOR AND BENEFITS OF THE PLACING AND THE TOP-UP SUBSCRIPTION AND USE OF PROCEEDS" in the Announcements.

By Order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Mr. Tan Zheng
Chairman and Executive Director

Hong Kong, 5 February 2026

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.

All Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.